Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
Company profile
Ticker
TROV
Exchange
Website
CEO
Thomas H. Adams
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Healthcare Recoveries Inc
SEC CIK
Corporate docs
IRS number
611141758
Latest filings (excl ownership)
SC 13E3/A
Going private transaction (amended)
16 Jul 04
15-12G
Securities registration termination
15 Jul 04
8-K
Stockholders Approve Sale of Trover Solutions
13 Jul 04
DEFA14A
Additional proxy soliciting materials
13 Jul 04
DEFM14A
Proxy related to merger
15 Jun 04
SC 13E3/A
Going private transaction (amended)
15 Jun 04
PRER14A
Preliminary revised proxy
27 May 04
SC 13E3/A
Going private transaction (amended)
27 May 04
10-Q
2004 Q1
Quarterly report
14 May 04
DEFA14A
Additional proxy soliciting materials
14 May 04
Latest ownership filings
No filings